A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Rubio-Pérez L, Lázaro-Gorines R, Harwood SL, Compte M, Navarro R, Tapia-Galisteo A, Bonet J, Blanco B, Lykkemark S, Ramírez-Fernández Á, Ferreras-Gutiérrez M, Domínguez-Alonso C, Díez-Alonso L, Segura-Tudela A, Hangiu O, Erce-Llamazares A, Blanco FJ, Santos C, Rodríguez-Peralto JL, Sanz L, Álvarez-Vallina L.
Rubio-Pérez L, et al. Among authors: blanco b, blanco fj.
Oncoimmunology. 2023 Apr 24;12(1):2205336. doi: 10.1080/2162402X.2023.2205336. eCollection 2023.
Oncoimmunology. 2023.
PMID: 37114242
Free PMC article.